文献速递间质性肺疾病呼吸道感染

肺微生物群促进肺纤维化中的肺部炎症与疾病进展

Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

该研究结合68例IPF患者BAL液菌群分析与小鼠纤维化模型,发现肺菌群失调可预测疾病进展、与肺泡促纤维化细胞因子相关,并在小鼠中先于肺损伤峰值出现且持续存在;无菌动物缺乏微生物组可免于死亡,提示肺微生物群参与IPF进展。

要点

  • IPF患者肺细菌负荷可预测纤维化进展。
  • 菌群多样性与组成同肺泡促纤维化细胞因子升高相关。
  • 小鼠肺菌群失调先于肺损伤峰值且持续存在。

核心结论

  • 肺微生物群参与IPF疾病进展,肺菌群失调可能促进肺泡炎症与异常修复。

研究设计与样本

  • 人类研究:分析68例IPF患者BAL液肺微生物群。
  • 动物研究:采用常规与无菌小鼠的肺纤维化模型。
  • 采用16S rRNA基因测序及针对低生物量样本优化的新技术表征肺细菌。

主要发现

  • 肺微生物组紊乱可预测疾病进展,并与局部宿主炎症相关。
  • IPF患者肺细菌负荷可预测纤维化进展。
  • 菌群多样性与组成同肺泡促纤维化细胞因子升高相关。
  • 小鼠纤维化模型中肺菌群失调先于肺损伤峰值且持续存在。
  • 无菌动物缺乏微生物组可免于死亡。

临床怎么用

  • 肺微生物群可能作为IPF治疗的新靶点。
  • 对IPF患者关注肺菌群失调或有助于风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Idiopathic pulmonary fibrosis (IPF) causes considerable global morbidity and mortality, and its mechanisms of disease progression are poorly understood. Recent observational studies have reported associations between lung dysbiosis, mortality, and altered host defense gene expression, supporting a role for lung microbiota in IPF. However, the causal significance of altered lung microbiota in disease progression is undetermined. Objectives: To examine the effect of microbiota on local alveolar inflammation and disease progression using both animal models and human subjects with IPF. Methods: For human studies, we characterized lung microbiota in BAL fluid from 68 patients with IPF. For animal modeling, we used a murine model of pulmonary fibrosis in conventional and germ-free mice. Lung bacteria were characterized using 16S rRNA gene sequencing with novel techniques optimized for low-biomass sample load. Microbiota were correlated with alveolar inflammation, measures of pulmonary fibrosis, and disease progression. Measurements and Main Results: Disruption of the lung microbiome predicts disease progression, correlates with local host inflammation, and participates in disease progression. In patients with IPF, lung bacterial burden predicts fibrosis progression, and microbiota diversity and composition correlate with increased alveolar profibrotic cytokines. In murine models of fibrosis, lung dysbiosis precedes peak lung injury and is persistent. In germ-free animals, the absence of a microbiome protects against mortality. Conclusions: Our results demonstrate that lung microbiota contribute to the progression of IPF. We provide biological plausibility for the hypothesis that lung dysbiosis promotes alveolar inflammation and aberrant repair. Manipulation of lung microbiota may represent a novel target for the treatment of IPF.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. O'Dwyer DN, Ashley SL, Gurczynski SJ, et al. Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019. PMID: 30789747. doi:10.1164/rccm.201809-1650OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。